

Progress through tyrosine kinase inhibitor (TKI) therapies in rare sarcoma subtypes

Thursday 14 March 2024

13:00–14:00 CET

Hall B1, Palazzo dei Congressi,
Lugano, Switzerland

Welcome and introduction

Peter Reichardt, Berlin, Germany

Evolution of the role of local therapies for the treatment of GIST & TGCT

Alessandro Gronchi, Milan, Italy

Unmet need and changing treatment landscape for TGCT patients

Hans Gelderblom, Leiden, The Netherlands

Overview of the recent changes and remaining unmet needs in GIST

Axel Le Cesne, Villejuif, France

Discussion and conclusions

All faculty

This is a non-promotional meeting.
This meeting is organised and funded by Deciphera.
This invitation has been written and sponsored by Deciphera.
It is intended for healthcare professionals only.

© 2024 Deciphera Pharmaceuticals, LLC. Deciphera and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.

DCPH-M00527 | February 2024

deciphera[®]